CoChat

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out). Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00415-006-0218-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534–551 · DOI · Paper page

Cited by

See all 172

Metadata

Authors
Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D.
Affiliations
  • Universität Innsbruck (AT)
  • Kantonsspital Münsterlingen (CH)
Corresponding author
Wissel, Jörg
Venue
Journal of Neurology
Published
2006-09-20
Volume
253
Issue
10
Pages
1337-1341
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
OpenAlex
W2167045148
Cited by
171
References
31
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 11 · 2021: 7 · 2020: 12 · 2019: 4 · 2018: 18 · 2017: 10 · 2016: 9 · 2015: 10 · 2014: 9 · 2013: 2 · 2012: 9
FWCI
6.47
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
  • Health Sciences › Medicine › Rehabilitation › Cerebral Palsy and Movement Disorders
Keywords
nabilone, spasticity-related pain, upper motor neuron syndrome, multiple sclerosis, synthetic cannabinoids, low-dose therapy, pain management, drug safety, adverse effects
MeSH terms
Activities of Daily Living, Adolescent, Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Muscle Spasticity, Pain, Pain Measurement, Recurrence, Dronabinol, Motor Neuron Disease, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. https://app.cochat.ai/papers/10.1007/s00415-006-0218-8
The paper
Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006). Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. Journal of Neurology. https://doi.org/10.1007/s00415-006-0218-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.